ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …
…, VV McLaughlin, SL Archer, DB Badesch… - Circulation, 2009 - Am Heart Assoc
Pulmonary hypertension (PH) is a complex, multidisciplinary disorder. Recent advances
have led to increased recognition and new therapies. While some data exist to form …
have led to increased recognition and new therapies. While some data exist to form …
Definitions and diagnosis of pulmonary hypertension
…, T Satoh, F Torres, MR Wilkins, DB Badesch - Journal of the American …, 2013 - jacc.org
… Badesch has received grant funding from Actelion/CoTherix, Gilead, Pfizer, United
Therapeutics/Lung Rx, Eli Lilly/ICOS, Bayer, Novartis, Ikaria, and ARIES ; has served as a consultant (…
Therapeutics/Lung Rx, Eli Lilly/ICOS, Bayer, Novartis, Ikaria, and ARIES ; has served as a consultant (…
Diagnosis and assessment of pulmonary arterial hypertension
DB Badesch, HC Champion… - Journal of the American …, 2009 - jacc.org
… Badesch has received honoraria for service on steering committees and advisory boards
from Actelion (CoTherix), Biogen IDEC, Encysive, Gilead (Myogen), GlaxoSmithKline, Lilly, …
from Actelion (CoTherix), Biogen IDEC, Encysive, Gilead (Myogen), GlaxoSmithKline, Lilly, …
[HTML][HTML] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
…, MD McGoon, S Rich, DB Badesch… - … England Journal of …, 1996 - Mass Medical Soc
Background Primary pulmonary hypertension is a progressive disease for which no treatment
has been shown in a prospective, randomized trial to improve survival. Methods We …
has been shown in a prospective, randomized trial to improve survival. Methods We …
[HTML][HTML] Bosentan therapy for pulmonary arterial hypertension
Background Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a
preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved …
preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved …
[HTML][HTML] Sildenafil citrate therapy for pulmonary arterial hypertension
…, RJ Barst, LJ Rubin, D Badesch… - … England Journal of …, 2005 - Mass Medical Soc
Background Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic
guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate–…
guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate–…
Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management …
…, CS Coffey, A Frost, RJ Barst, DB Badesch… - Circulation, 2010 - Am Heart Assoc
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …
clinical management. A quantitative survival prediction tool has not been established for …
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial
DB Badesch, VF Tapson, MD McGoon… - Annals of internal …, 2000 - acpjournals.org
Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …
scleroderma spectrum of disease for which no treatment has been proven effective in a …
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
…, IM Robbins, A Frost, VF Tapson, DB Badesch… - The Lancet, 2001 - thelancet.com
Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen, might be a
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
cause of pulmonary hypertension. We describe the efficacy and safety of bosentan, a dual …
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
DB Badesch, GE Raskob, CG Elliott, AM Krichman… - Chest, 2010 - Elsevier
Background The Registry to EValuate Early And Long-term pulmonary arterial hypertension
disease management (REVEAL Registry) was established to provide updated …
disease management (REVEAL Registry) was established to provide updated …